AD

1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid methanesulfonate hydrate (1:1:1)(CAS: 223652-90-2)

1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid methanesulfonate hydrate (1:1:1)
CAS Number

Related Products

Other Suppliers for 1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid methanesulfonate hydrate (1:1:1)

Basic Information

Molecular Formula
C24H26F2N2O8S
Molecular Weight
540.54 g/mol

Physical Properties

Boiling Point
581.5 °C at 760 mmHg
Flash Point
581.5 °C at 760 mmHg

Chemical Identifiers

SMILES
CC1C2=C(CN1)C=C(C=C2)C3=C(C4=C(C=C3)C(=O)C(=CN4C5CC5)C(=O)O)OC(F)F.CS(=O)(=O)O.O
InChIKey
IGTHEWGRXUAFKF-NVJADKKVSA-N

Database References

MDL Number
MFCD12031996

FAQ

This compound requires adherence to several regulatory guidelines. Under the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), it may be classified as a hazardous substance. In Europe, it must comply with REACH regulations for registration, evaluation, authorization, and restriction of chemicals. For FDA and EPA requirements, specific toxicity, chemical stability, and environmental impact studies must be conducted. Manufacturers and importers are also required to provide Material Safety Data Sheets (MSDS) and ensure proper labeling as per local and international standards.
There are alternative compounds that can be used as substitutes in synthesis. For example, analogs such as 1-Cyclopropyl-8-methoxy-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid methanesulfonate hydrate can be considered. Other common alternative reagents might include difluoromethanol or other similar dihydroisoquinoline derivatives. These alternatives can offer similar functionalities with varying degrees of efficacy and cost.
The market and research for this compound are growing, driven by its potential applications in medicinal chemistry and drug development. There is a focus on understanding its pharmacological properties and exploring its use as a lead compound in the treatment of various diseases, particularly those related to inflammation and neurodegenerative disorders. Recent research trends indicate an increasing interest in its biosynthetic pathways and synthetic methods for enhanced production and purity.
Waste containing this compound should be managed carefully to ensure safety and compliance with environmental regulations. Waste collection should be conducted in sealed containers to prevent spillage and contamination. For incineration, use specialized facilities designed for hazardous waste disposal. For professional waste disposal, consult with authorized waste management companies. Always follow local and international environmental protection guidelines to minimize the environmental impact and ensure worker safety during disposal operations.

Safety Notice

Please verify product specifications and safety data before use. Contact the supplier for detailed safety information.

Always follow proper handling procedures

Contact Information

Email

sales02@reliabpharma.com

Mobile

15902102743

Telephone

021-67676847-8008

Fax

021-67676384